Diagnosing lung cancer using etoposide microparticles labeled with 99mTc

The diagnosis of lung cancer mostly occurs when the cancer is already in an advanced stage. In this situation, there are few options for the treatment and most of them have few chances of success. In this study, we developed and tested etoposide microparticles as a diagnostic agent for imaging lung...

Full description

Saved in:
Bibliographic Details
Published inArtificial cells, nanomedicine, and biotechnology Vol. 46; no. 2; pp. 341 - 345
Main Authors Salvi, Roberto, Cerqueira-Coutinho, Cristal, Ricci-Junior, Eduardo, dos Santos, Sofia Nascimento, Pinto, Suyene Rocha, Bernardes, Emerson Soares, Barros de Araujo, Patricia Lopes, Santos-Oliveira, Ralph
Format Journal Article
LanguageEnglish
Published Abingdon Taylor & Francis 01.03.2018
Taylor & Francis Ltd
Subjects
Cancer
Computed tomography
Developmental stages
Diagnostic systems
Etoposide
Kidneys
Liver
Lung cancer
Medical imaging
micro-radiopharmaceuticals
Microparticles
nuclear medicine
oncology
Radiopharmaceuticals
Single photon emission computed tomography
Spleen
Technetium
Online AccessGet full text

Cover

More Information
Summary:The diagnosis of lung cancer mostly occurs when the cancer is already in an advanced stage. In this situation, there are few options for the treatment and most of them have few chances of success. In this study, we developed and tested etoposide microparticles as a diagnostic agent for imaging lung cancer at early stages of development. We tested etoposide microparticles labeled with technetium 99m in inducted mice. The results demonstrated that over 10% of the total dose used was uptake by the tumor site. Also, the results showed that the microparticles had a good renal clearance and low uptake by liver and spleen. The data suggest that these micro-radiopharmaceuticals may be used for lung cancer imaging exam, especially single-photo emission computed tomography (SPECT).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2169-1401
2169-141X
DOI:10.1080/21691401.2017.1307848